Neurocrine BiosciencesNASDAQ: NBIX

Jefferies Global Healthcare Conference on June 5 in New York Goldman Sachs 45th Annual Global Healthcare Conference on June 13 in Miami SAN DIEGO, May 29, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in June. Kevin Gorman, Chief Executive Officer, Kyle Gano, Chief Business Development and Strategy Officer, and Matt Abernethy, Chief Financial Officer will present at the Jefferies Global Healthcare Conference at 2:30 p.m.

Neurocrine Biosciences CEO Kevin Gorman will retire on Oct. 11 after three decades with the company that he founded and will be succeeded by insider Kyle Gano.

Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D.

SAN DIEGO , May 21, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA® (valbenazine) capsules in the Journal of Clinical Psychopharmacology . The analysis assessed long-term outcomes relevant to the real-world management of tardive dyskinesia (TD) and demonstrated that nearly all study participants met the threshold for clinically meaningful improvements in TD symptom severity by Week 48.

While the revenue and EPS of Neurocrine (NBIX) provide insight into its performance in the first quarter of 2024, it is important to also analyze how certain key metrics stack up against Wall Street expectations and the figures from the same period last year.

Neurocrine Biosciences (NBIX) reported earnings of $0.42 per share for the quarter, falling short of the Zacks Consensus Estimate of $1.04 per share. This is an improvement from the loss of $0.79 per share reported in the same quarter last year.

On Tuesday, Neurocrine Biosciences announced that the FDA has given approval for the granule formulation of their drug to treat movement disorders linked to Huntington's disease.

Look beyond analysts' expectations for Neurocrine (NBIX) and consider projections for key metrics to better understand the company's performance in the first quarter of 2024.

Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted spending to grow the Ingrezza business (Huntington's chorea and long-term care facilities) and prepare the market for the eventual crinecerfont launch. Neurocrine has a number of Phase II read-outs coming in 2024, and while these are high-risk programs, compelling efficacy data could drive meaningful share price upside.